Shalby share price
NSE: SHALBYPharma & HealthcareMedical Care Facilities
Shalby at a glance
Shalby (NSE: SHALBY) closed at ₹126.00 on 19 Oct 2026, down 2.33% on the day. With a market capitalisation of ₹1,361 Cr, it ranks 1325th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 38.9× trailing earnings, against a return on equity of 3.7% in FY26. Over the past year the share price has fallen 49.9%. Its 52-week range is ₹125.82 (30 Mar 2026) to ₹254.95 (21 Oct 2025); the last close is 50.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹287 Cr (+8.5% year on year) and net profit ₹18 Cr, on a consolidated basis. Promoters held 74.33% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,361 CrRank 1325 on NSE
- P/E (trailing)
- 38.9×
- Price to book
- 1.36×FY26
- EPS (TTM)
- ₹3.23to Q4 FY26
- ROE
- 3.7%FY26
- ROCE
- 7.9%FY26
- Debt to equity
- 0.54FY26
- Net profit margin
- 3.0%FY26
- Book value / share
- ₹93.49FY26
- 52-week high
- ₹254.9521 Oct 2025
- 52-week low
- ₹125.8230 Mar 2026
- 1-year return
- −49.9%
- RSI (14-day)
- 31.8
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.33% | −6.0% | −8.6% | −24.1% | −49.9% |
Shalby quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹279 Cr | ₹268 Cr | ₹276 Cr | ₹265 Cr | ₹296 Cr | ₹285 Cr | ₹272 Cr | ₹287 Cr |
| Revenue YoY | +18.4% | +12.4% | +27.6% | +8.5% | +6.3% | +6.7% | −1.3% | +8.5% |
| Net profit | ₹15 Cr | ₹2 Cr | −₹3 Cr | −₹12 Cr | ₹8 Cr | ₹7 Cr | ₹1 Cr | ₹18 Cr |
| Net profit YoY | −29.2% | −91.4% | −115.7% | −176.0% | −47.9% | +208.5% | — | — |
| Net margin | 5.3% | 0.9% | −1.1% | −4.6% | 2.6% | 2.6% | 0.5% | 6.4% |
| EPS | ₹1.37 | ₹0.22 | −₹0.28 | −₹1.13 | ₹0.71 | ₹0.68 | ₹0.12 | ₹1.72 |
Shalby financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹431 Cr | ₹699 Cr | ₹805 Cr | ₹934 Cr | ₹1,087 Cr | — |
| Operating profit | ₹55 Cr | ₹84 Cr | ₹102 Cr | ₹128 Cr | ₹56 Cr | — |
| Net profit | ₹42 Cr | ₹54 Cr | ₹68 Cr | ₹84 Cr | ₹2 Cr | — |
| EPS (₹) | ₹4.00 | ₹5.00 | ₹6.00 | ₹8.00 | ₹0.00 | — |
| Cash from operations | ₹84 Cr | ₹19 Cr | ₹68 Cr | ₹20 Cr | −₹4 Cr | — |
| Total debt | ₹36 Cr | ₹87 Cr | ₹67 Cr | ₹176 Cr | ₹137 Cr | ₹153 Cr |
| Shareholders' equity | ₹835 Cr | ₹876 Cr | ₹928 Cr | ₹1,000 Cr | ₹992 Cr | ₹1,005 Cr |
Shalby shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.27% | 74.27% | 74.33% | 74.33% | 74.33% | 74.33% |
| Foreign institutions | 4.54% | 5.20% | 4.64% | 4.47% | 4.36% | 4.46% |
| Domestic institutions | 0.18% | 0.20% | 0.20% | 0.20% | 0.25% | 0.30% |
| Non-institutions | 20.33% | 19.64% | 20.18% | 20.35% | 20.41% | 20.26% |
Shalby vs peers
The listed Pharma & Healthcare companies nearest to Shalby by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AMRUTANJANAmrutanjan Health Care | ₹501.00 | −3.09% | −28.8% | ₹1,448 Cr | 25 | — |
| JAGSNPHARMJagsonpal Ser | ₹217.95 | −0.07% | −1.3% | ₹1,435 Cr | 34.5 | — |
| AHCLAnlon Healthcare | ₹26.92 | −0.22% | +108.5% | ₹1,431 Cr | 44.1 | — |
| TTKHLTCARETTK Healthcare | ₹1,007.60 | −2.93% | −12.2% | ₹1,424 Cr | 21.7 | — |
| SHALBYShalby | ₹126.00 | −2.33% | −49.9% | ₹1,361 Cr | 38.9 | — |
| KOPRANKopran | ₹279.00 | +2.01% | +61.2% | ₹1,347 Cr | 52.3 | — |
| FERMENTAFermenta Biotech | ₹456.75 | −6.31% | — | ₹1,344 Cr | — | — |
Ask anything about Shalby
Pivot answers on the live chart with evidence you can check, and tests strategies against SHALBY's own history. Try: “Why has SHALBY moved over the last three months?” · “Backtest a 50-day moving-average crossover on SHALBY over five years” · “Compare SHALBY with AMRUTANJAN on margins and valuation”
Frequently asked questions about Shalby
What is the share price of Shalby today?
Shalby (NSE: SHALBY) last closed at ₹126.00 on 19 Oct 2026. Its 52-week high is ₹254.95 and its 52-week low is ₹125.82.
What is the market cap of Shalby?
Shalby's market capitalisation is ₹1,361 Cr (₹1,361 Cr) at the 19 Oct 2026 close, ranking 1325th among the NSE companies Pivot tracks.
What is the P/E ratio of Shalby?
Shalby trades at a trailing P/E of 38.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 34.5.
What is the ROE and ROCE of Shalby?
Return on equity was 3.7% in FY26 and return on capital employed was 7.9% in FY26 (consolidated figures).
Is Shalby a debt-free company?
No. Shalby's debt-to-equity ratio was 0.54 in FY26, with total debt of ₹153 Cr.
What were Shalby's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Shalby reported revenue of ₹287 Cr, +8.5% year on year, and net profit of ₹18 Cr.
How has Shalby stock performed over the last year?
Shalby's share price has fallen 49.9% over the past year, −24.1% over three months and −8.6% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Shalby?
As of 30 Jun 2026: promoters 74.33%, foreign institutions 4.46%, domestic institutions 0.30%, non-institutions 20.26%.
Who are Shalby's competitors?
The listed Pharma & Healthcare companies closest to Shalby by market cap are Amrutanjan Health Care, Jagsonpal Ser, Anlon Healthcare, TTK Healthcare, Kopran and Fermenta Biotech.
Is Shalby a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Shalby's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHALBY against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text